US-based Insmed (Nasdaq GS: INSM) has reported mixed results from its Phase II clinical trial of Arikayce (liposomal amikacin for inhalation), for the treatment of patients with treatment resistant non-tuberculous mycobacterial (NTM) lung infections.
The randomized, double-blind, placebo-controlled trial compared Arikayce added to standard of care treatment, versus standard of care treatment plus placebo, in 90 adult patients with treatment resistant NTM lung disease. The primary efficacy endpoint of the study was a semi-quantitative measurement of the change in mycobacterial density on a seven-point scale from baseline (day one) to the end of the randomized portion of the trial (day 84). Arikayce did not meet the pre-specified level for statistical significance although there was a positive trend in favor of Arikayce.
Secondary endpoint provides good news
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze